CHRO
Channel Therapeutics Corp
$
13.800
- Overview
- Forecast
- Valuation
- Earnings
High
13.799999999999999
Open
13.799999999999999
VWAP
--
Vol
--
Mkt Cap
--
Low
13.799999999999999
Amount
--
EV/EBITDA(TTM)
--
Total Shares
6.60M
EV
3.25M
EV/OCF(TTM)
--
P/S(TTM)
--
Channel Therapeutics Corporation is engaged in developing innovative, non-addictive, drugs to treat chronic neuropathic and acute and chronic eye pain. The Company is focused on the development of non-opioid pain treatment therapeutics with a focus on modulating NaV1.7 receptors responsible for sensing and transmitting pain in the peripheral nervous system. It is initially targeting orphan chronic pain indications, specifically small fiber neuropathy and erythromelalgia, and acute and chronic eye pain. The Company’s patented, selective, and potent (nM) inhibitor of human NaV1.7 has demonstrated additional efficacy in several models of pain: acute, chronic, inflammatory, visceral, post-surgical, and chemotherapy-induced.
Show More
Valuation Metrics
The current forward P/E ratio for Channel Therapeutics Corp (CHRO.A) is -1.23, compared to its 5-year average forward P/E of -1.28. For a more detailed relative valuation and DCF analysis to assess Channel Therapeutics Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-1.28
Current PE
-1.23
Overvalued PE
-0.64
Undervalued PE
-1.92
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q1
YoY :
-5.17%
-1.83M
Operating Profit
FY2025Q1
YoY :
-23.21%
-1.97M
Net Income after Tax
FY2025Q1
YoY :
-41.82%
-0.32
EPS - Diluted
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
5
25.8K
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
5
25.8K
USD
Months
CHRO News & Events
Events Timeline
2025-05-14 (ET)
2025-05-14
08:14:35
Channel Therapeutics announces efficacy results for eye drop formulations
2025-04-17 (ET)
2025-04-17
06:03:55
Ligand subsidiaries, Chromocell Therapeutics to merge
2024-12-20 (ET)
2024-12-20
08:10:58
Channel Therapeutics highlights difference between NaV1.7, NaV1.8
Sign Up For More Events
Sign Up For More Events
News
5.0
07-10BenzingaPelthos Therapeutics Launches First At-Home Prescription Gel For Highly Contagious Skin Disease
8.5
07-02NASDAQ.COMLigand, Pelthos Close Merger Deal With Channel's CHRO; To Launch ZELSUVMI In July
8.5
07-02NewsfilterPelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement
Sign Up For More News
People Also Watch
CSCI
COSCIENS Biopharma Inc
4.190
USD
0.00%
RLMD
Relmada Therapeutics Inc
0.625
USD
+1.79%
SCKT
Socket Mobile Inc
1.200
USD
-0.66%
ADGM
Adagio Medical Holdings Inc
1.690
USD
+7.85%
SVMH
SRIVARU Holding Ltd
0.730
USD
0.00%
IVDA
Iveda Solutions Inc
2.300
USD
+4.55%
ASTC
Astrotech Corp
5.600
USD
-0.53%
MYNA
Mynaric AG
0.250
USD
-61.26%
MNDR
Mobile-health Network Solutions
1.065
USD
-0.47%
TLPH
Talphera Inc
0.400
USD
-4.08%
FAQ
What is Channel Therapeutics Corp (CHRO) stock price today?
The current price of CHRO is 13.799999999999999 USD — it has increased 6.67 % in the last trading day.
What is Channel Therapeutics Corp (CHRO)'s business?
What is the price predicton of CHRO Stock?
What is Channel Therapeutics Corp (CHRO)'s revenue for the last quarter?
What is Channel Therapeutics Corp (CHRO)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Channel Therapeutics Corp (CHRO)'s fundamentals?
How many employees does Channel Therapeutics Corp (CHRO). have?